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INTRODUCTION 
At the end of the first epilepsy needs document 
(‘Needs I ‘) in 1993’, we noted the opportunity for 
epilepsy to move further up the health service agenda 
and concluded with a commitment to review the paper 
in 5 years time. Now that 5 years have elapsed, we take 
stock of some changes and revisit epilepsy needs in 
the UK. 
Needs 1 has run to some 20 000 reprints, and has been 
cited in many other publications. Out of it there arose 
an initiative called the Epilepsy Task Force** which in 
turn has produced documentation to assist health man- 
agers and planners in developing epilepsy services’.3, 
using Needs I as its basis. The Task Force Specifica- 
tion for Epilepsy Services was appended to an England 
& Wales NHS Executive Letter EL(95)120 from the 
NHS Executive Director of Planning in January 19964. 
The effect of this executive letter has been studied5. 
Needs 1 therefore had an impact. Does it need revising? 
We feel it is appropriate to do so to take into account 
the changes in the structure of the NHS together with 
changes in the possibilities for treating epilepsy and 
developments in some specialist areas. This paper is 
mainly concerned with the situation in the UK, and 
seeks to identify needs which could and should be 
met through the National Health Service. Mention will 
also be made of the crucial importance of inter-agency 
liaison between health, social services and education. 
** Correspondence address: The Epilepsy Task Force Secretariat, 
PO Box 16696, London WC I A 2PD. 
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DEFINITION AND BORDERLANDS 
An epileptic seizure is a brief, usually unprovoked, 
stereotyped disturbance of consciousness, behaviour, 
emotion, motor function or sensation which on clinical 
grounds results from cortical neuronal discharge. 
Seizures that occur during or after a known or sus- 
pected cerebral insult are referred to as acute symp- 
tomatic seizures. Where seizures occur in the ab- 
sence of a presumed acute precipitating insult the term 
unprovoked seizures is used. These may be symp- 
tomatic or idiopathic/cryptogenic. Symptomatic un- 
provoked seizures are also called remote symptomatic 
seizures, and may occur in individuals who have well- 
demonstrated antecedent conditions known to be asso- 
ciated with seizures, such as cerebrovascular accident, 
penetrating head injuries, cerebral palsy or develop- 
mental abnormalities of the central nervous system. 
Epilepsy is a condition characterized by recurrent 
unprovoked seizures. Many types of epileptic seizure 
are recognized, and the precise descriptions of seizure 
types together with other clinical data characterize spe- 
cific epileptic syndromes. A syndrome diagnosis may 
give clues to aetiology and prognosis, and has implica- 
tions for the choice of treatment. 
Epilepsy is frequently overdiagnosed. In adults the 
most common cause of misdiagnosis is syncope, which 
may sometimes be a symptom of another, treatable, car- 
diac condition. Other conditions that may be mistaken 
for epilepsy include hysterical dissociative phenom- 
ena and panic disorder. In childhood, reflex anoxic and 
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breath-holding attacks are often misdiagnosed. Mis- 
diagnosis carries a dual penalty-unnecessary treat- 
ment for epilepsy together with a failure to treat the 
unrecognized actual disease. A quality epilepsy service 
will be able to address these issues and will be cost- 
effective in terms of both health gain and economics. 
EPIDEMIOLOGY 
Incidence, prevalence and mortality rates 
Epilepsy is the most common serious neurological con- 
dition with a prevalence in the community about ten- 
fold higher than that of multiple sclerosis and 100 times 
higher than that of motor neurone disease. 
The annual incidence rate worldwide has been found 
usually to fall between 40- 100 cases/ 100 000 persons. 
A recent UK study in a population of over two mil- 
lion persons, found an incidence rate of newly treated 
epilepsy of 80.8/100000 (95% confidence intervals 
(CI) 76.9-84.7) in 199S6. Age-specific incidence rates 
are highest in young children and in the elderly, and 
lowest in young adulthood and middle age. In the first 
year of life, the incidence of epilepsy is reported at be- 
tween 70-220/100000. It falls to 50-150/100000 by 4 
to 5 years, and stays at about 50-70/100 000 throughout 
the rest of childhood’. 
The prevalence rate of epilepsy has usually been 
found to lie between 5-l O/l 000 persons, and is highest 
in old age. The UK overall prevalence rate of treated 
epilepsy is 5.15/1000 (95% CI 5.05-5.25). The preva- 
lence rises from 2-7/1000 children at 2 years of age 
to 4-14/1000 by 15 years. The lifetime prevalence is 
between 2-5% of the population. 
Mortality rates of individuals with epilepsy are be- 
tween 2-4 times that of the age-matched popula- 
tion without epilepsy. The excess mortality is greatest 
amongst children and young adults and the standard- 
ized mortality rate is highest in the 10 years after diag- 
nosis. Of particular concern is sudden unexpected death 
in epilepsy (SUDEP), which is probably usually due to 
central respiratory arrest during seizures, and which 
occurs at an annual rate of about l/100-200 persons 
with chronic active epilepsy*. 
CLINICAL CHARACTERISTICS OF EPILEPSY 
IN THE POPULATION 
Seizure types and syndromes 
Approximately 60% of patients have tonic-clonic 
seizures (including 20% with secondarily generalized 
seizures), 20% complex partial seizures, 12% mixed 
tonic-clonic and partial seizures, about 3% simple par- 
tial seizures, and less than 5% absence seizures, my- 
oclonic seizures and other seizure types. 
About one-third of cases have less than one seizure 
a year, one-third have between one and 12 seizures 
per year, and the remainder more than one seizure per 
month (20% of these have more than one seizure per 
week). 
Up to 60% of people with active epilepsy have ad- 
ditional neurological or neuropsychological handicaps, 
e.g. learning disabilities, behavioural disturbances, dis- 
crete cognitive impairment, focal neurological deficit. 
Of patients seen by a paediatrician 15% will have 
severe epilepsy. West Syndrome, characterized by in- 
fantile spasms, accounts for at least 3% of childhood 
epilepsy, and the Lennox-Gastaut Syndrome (a condi- 
tion in which refractory epilepsy occurs in the context 
of learning difficulties and cognitive deterioration in 
childhood) up to 6%. Childhood absence epilepsy oc- 
curs in 8%. 
Thus in the general population, epilepsy occurs in 
a range of people from those who are otherwise nor- 
mal to those with profound learning disability (mental 
handicap). One-third of people with learning disability 
have seizures. 
In a population of 100 000 such as that served by a 
Primary Care Group in the UK, there will be about 80 
new cases of epilepsy per year, and about 5 15 people 
under treatment for epilepsy. Of these, more than 170 
will be having more than one seizure a month, and up 
to 300 may have additional handicaps. There will be 
one or two deaths per year from SUDEP. 
Aetiology 
Recent advances in Magnetic Resonance Imaging 
(MRI) have allowed the identification of aetiologies 
which were previously hidden. In populations of pa- 
tients with chronic epilepsy, the underlying cause can 
now be determined in over two-thirds of cases. How- 
ever, the frequency with which underlying causes can 
be uncovered in populations of newly diagnosed pa- 
tients with the application of advanced MRI has not 
been fully established. Epilepsies in which no under- 
lying cause can be found are best referred to as cryp- 
togenic. With advances in imaging and genetic tech- 
niques, the proportion of cryptogenic cases is likely to 
diminish. 
Of defined causes, the most common are cerebrovas- 
cular disease; cerebral tumours; genetic, congenital or 
hereditary conditions; alcohol, drugs and other toxic 
causes; head trauma (including post-neurosurgery); 
and post-infective causes (encephalitis and meningitis). 
Between lo-20% have idiopathic generalized epilepsy 
(IGE). 
The potential for preventing epilepsy currently rests 
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with improvements in the treatment of vascular dis- 
ease and infections, and the avoidance of trauma, al- 
cohol and other toxic causes. Improved pre-natal and 
peri-natal care might reduce the incidence of congenital 
causes of epilepsy, although in most cases, the nature of 
the pre- or peri-natal abnormality resulting in epilepsy 
is not fully understood. 
Much of the secondary handicap of epilepsy, how- 
ever, whether physical, psychological or social, is em- 
inently preventable by appropriate medical and social 
management. 
COST AND BURDEN9 
The annual medical costs of newly diagnosed epilepsy 
in the UK have been estimated to be in the region of 
fl8 million and the total annual costs of established 
epilepsy in the region off2 billion”. Epilepsy has been 
estimated to account for about 0.2% of all UK general 
practice costs and 0.6% of all UK hospital costs. The 
pharmaceutical costs in the UK have risen by 220% 
in the past 5 years and now account for over f60 mil- 
lion annually. As the population demographics change, 
and the number of patients with epilepsy in the elderly 
age group rises, medical costs are likely to increase. It 
is also easy to underestimate the burden to parents of 
caring for a child with epilepsy. 
In developing countries there is still a large ‘treat- 
ment gap’ in epilepsy, and studies have shown that, at 
any one time, between 80-95% of patients are not re- 
ceiving drug therapy. This is largely due to a failure 
to provide adequate medical services. In the UK, too, 
at a rough approximation, 30% of patients with active 
epilepsy are not on therapy. 
EVALUATING THE EVIDENCE 
When guidelines are developed, recommendations are 
weighted by levels, based on the type of evidence that 
underwrites them”. ‘Level I’ meta-analysis and ran- 
domized controlled trials provide the best information 
to recommend best practice. Unfortunately, there has 
been little research on this quality so far, apart from that 
on the effectiveness of antiepileptic drugs. As this doc- 
ument shows, although the research evidence is lack- 
ing, this does not mean that there are not considerable 
problems with the present level of care for patients 
with epilepsy. If progress is to be made, planning will 
have to be based on ‘Level II, III, and IV’ evidence 
from controlled studies, comparisons of care, and peer 
recommendations. There is a need for good quality re- 
search to demonstrate the most effective models for 
epilepsy ca.re12* 13. 
MANAGEMENT OF INITIAL PRESENTATION 
When a patient first has a seizure it usually presents 
to the general practitioner, whose task is to take a his- 
tory from the patient and any eye witnesses, provide 
the patient with information, and make a referral to an 
epilepsy specialist. A general practitioner will only see 
one or two new cases of epilepsy a year. This is insuf- 
ficient to develop skills in accurate diagnosis or initial 
treatment. Because of the potential problem of misdiag- 
nosis it is important that patients are seen quickly af- 
ter their first seizure by a consultant with an interest 
in epilepsy. General practitioners should not normally 
initiate treatment themselves unless the patient faces 
a long delay in seeing an epilepsy specialist. Then, 
the general practitioner could start antiepileptic drugs, 
preferably after discussion with the specialist. Use of 
local guidelines developed between primary and sec- 
ondary care help to clarify responsibility in initial di- 
agnosis and therapy. Relatively few districts have de- 
veloped local guidelines and there is a need to evaluate 
their effectiveness. 
Components of special initial assessment 
service 
Ideally this should be an adult or paediatric neurolog- 
ical outpatient clinic. However, neurology remains a 
relatively scarce speciality, and many epilepsy services 
continue to be run by other physicians with a special 
interest in the condition, such as clinical pharmaco- 
logists or neuropsychiatrists who have developed skills 
in epileptology. The function of this hospital-led ser- 
vice will be to (a) make a diagnosis, (b) initiate treat- 
ment, (c) provide initial counselling and information to 
patients and their families, (d) monitor the response to 
the initial treatment and (e) refer the patient back to the 
general practitioner if the condition is stable. The ser- 
vice needs to have a capacity to see more people than 
actually have epilepsy. For every five people who have 
epilepsy the clinic will need to see at least two others 
who do not. Furthermore, it is appropriate for a seizure 
assessment service to have an ongoing commitment to 
patients in whom the diagnosis remains unclear, or who 
have non-epileptic seizures. 
The forthcoming development of Primary Care 
Groups (PCGs) offers new opportunities. It may be 
possible for one general practitioner to develop further 
skills in managing epilepsy and work in close liaison 
with the district epilepsy services. This general practi- 
tioner would become the initial point of referral from 
his or her colleagues. PCGs will be responsible for 
developing ‘clinical governance’ for the patients they 
serve. There can be few chronic diseases better deserv- 
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ing of consideration for improvement since repeated 
general practice audits over the last 30 years show that 
over 40% of affected people continue to have seizures, 
and many do not receive adequate care, information 
and advice about their epilepsy. 
Investigations 
Epilepsy is primarily a clinical diagnosis. The elec- 
troencephalogram (EEG) is an aid to determining the 
epilepsy syndrome and therefore assists in deciding on 
appropriate treatment. The routine EEG is not a diag- 
nostic test for epilepsy. Every person with newly diag- 
nosed epilepsy will require at least one standard EEG 
recording to assist with syndrome diagnosis, and up to 
50% will require a second EEG. 
Patients presenting with partial (focal) epilepsy 
should have neuroimaging investigations unless there is 
a clear, previously existing cause for epilepsy. This will 
apply to 50-60% of children presenting with epilepsy, 
and to at least the same proportion in the 16-65 age 
group. In new patients over the age of 65, the percent- 
age requiring scanning may be lower because the aeti- 
ology may be clear already. MRI is superior to comput- 
erized tomography (CT) scanning in identifying lesions 
causing epilepsy, and is the preferred investigation. 
Identification of a structural lesion can have important 
treatment implications. Metabolic screening will be re- 
quired as part of the diagnostic process in about 10% 
of children, especially those presenting with epilepsy 
in the first year of life. 
Initial drug treatment 
Currently the majority of patients will receive ini- 
tial treatment with either sodium valproate or carba- 
mazepine as monotherapy. There are potential prob- 
lems with both of these drugs in women of childbear- 
ing age as they are both teratogenic. Lamotrigine has 
been licensed in monotherapy and may be used as ini- 
tial treatment’“, although, it is more expensive than 
valproate or carbamazepine. Some clinicians feel that 
it is too expensive to be used in monotherapy as a first- 
line drug but recent audited experience of its use in this 
role suggests that in monotherapy the effective dose is 
low so that its cost is not excessivei5. There is also ev- 
idence that gabapentin is effective in monotherapyt6, 
and this may be reflected in its licence in due course. 
The epileptic syndrome will influence the choice of 
drug, and it is important that care is taken over the initial 
diagnosis. Both valproate and lamotrigine have broad 
spectra of antiepileptic activity, while carbamazepine 
and gabapentin are most effective against partial-onset 
seizures. If used to treat primary generalized seizures, 
carbamazepine may make some types worse”, while 
gabapentin is ineffectiveis. 
In the early stages of treatment, patients whose 
epilepsy is refractory to these drugs or who are intoler- 
ant of them will be identified. In some of these cases, 
such as with localization-related epilepsy, phenytoin 
has been used as an alternative. However phenytoin 
is not recommended as a first-line antiepileptic drug 
due to its wide range of side effects. About one in 20 
children with childhood absence epilepsy may show a 
better response to ethosuximide or to a combination of 
ethosuximide and valproate. 
Where initial treatment does not control seizures, or 
where adverse reactions occur, there are a number of 
further medications and other treatment options which 
are referred to later in this paper. 
There are compelling reasons for ensuring continu- 
ity of formulation in antiepileptic drug prescribing. It 
is therefore appropriate to prescribe by brand and it 
should be regarded as unsatisfactory to make sudden 
switches from branded to generic formulations’9. 
CONTINUING CARE 
After the initial treatment plan has been instituted, it 
should be expected that 60-70% of patients will be- 
come seizure free and will return to the primary care 
service for continuing care. The 30-40% of patients 
who continue to experience seizures will need fur- 
ther specialist follow-up; but, if their seizures prove 
intractable, they too may be returned to primary care. 
Some patients who choose not to attend specialist clin- 
ics or not to take medication will also remain in primary 
care. 
The tasks involved in continuing care at a primary 
level are to monitor seizure frequency and drug side- 
effects, alter medication when indicated, provide en- 
couragement and support, and give information and 
counselling. Women with epilepsy need additional in- 
formation and advice about contraception and preg- 
nancy. Re-referral or access to specialist advice may 
be needed if seizures cannot be controlled; if cessation 
of treatment is possible, early in pregnancy, and for ad- 
vice about lifestyle issues such as driving. Serum drug 
level monitoring in primary care is of little help except 
when there are doubts about adherence to prescribed 
medication. It is difficult to see how these tasks can be 
performed without a structured annual review. Whilst 
most patients discuss their epilepsy with their general 
practitioners at least once a year, this is not usually 
done in a formal way. 
At present many general practitioners perceive a gap 
between the services that they currently provide for 
patients with epilepsy and the level of care they think 
that the patient should be receiving”. Management of 
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other chronic diseases such as diabetes and asthma is 
now routinely based in primary care. If primary care 
is to improve the level of care offered to patients with 
epilepsy then resources will need to be found. These 
extra resources could be used for district-based educa- 
tion, local guidelines, shared records, liaison through 
clinical nurse specialists, practice nurse run clinics, ac- 
cess to phone advice from the specialist and informa- 
tion sources, audit at practice and district levels, and 
a chronic management data set. All these ideas are al- 
ready being used by enthusiastic practices to improve 
the present level of service”. 
In secondary care the tasks of continuing care are to 
investigate intractable seizures, alter medication, assess 
for neurosurgery, advise on stopping treatment, man- 
age epilepsy in pregnancy, and to inform and educate 
patients. Liaison with primary care and patient orga- 
nizations is most effective when there is a team-based 
approach using specialist nurses. 
Epilepsy plus 
The 30%-40% of patients who continue to require ac- 
cess to specialist epilepsy services will do so because 
of one or more of the following problems: 
(a) seizures continue at an unacceptably high rate de- 
spite treatment; 
(b) the diagnosis remains uncertain; or 
(c) they have additional problems, such as additional 
neurological or psychiatric illness or learning dif- 
ficulties. 
Into this group of ‘epilepsy plus’ would also fall those 
referred back to the specialist service after initial as- 
sessment and treatment but who have developed ad- 
ditional epilepsy-related problems, or a deterioration 
in seizure control, although this last group should be 
numerically small. Nevertheless we would recommend 
that anyone who is still having seizures 2 years after 
diagnosis should be re-referred. At re-referral, critical 
assessment of the original diagnosis should be made 
and further appropriate investigations performed. If the 
diagnosis of epilepsy is no longer certain, special EEG 
studies to record a seizure should be undertaken if pos- 
sible (using ambulatory EEG monitoring with video 
records or telemetered EEG/video recording). A high 
quality MRI scan should be considered mandatory in 
all patients who continue to have seizures after 2 years. 
The range of possible therapies for the ‘epilepsy plus’ 
group includes exposure to second-line drugs, exposure 
to experimental drugs, epilepsy surgery, further assess- 
ment in a special assessment unit, alternative treatment 
options and neuropsychiatric follow-up. Other issues 
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that may have to be addressed are special educational 
referral, arrangements for care in the community and 
long-term care. 
New trends in antiepileptic drug treatment 
In the last 10 years several new antiepileptic drugs 
have come onto the market: vigabatrin, lamotrigine, 
gabapentin, topiramate and, most recently, tiagabine. 
All have been shown in double-blind controlled tri- 
als to be more effective than a placebo in controlling 
partial-onset seizures (with or without secondary gen- 
eralization). Meta-analysis of these trials suggests that 
none of them is more effective than any other although 
vigabatrin and topiramate had significantly more side 
effects than their corresponding placebo”. It should 
be remembered, however, that a clinical trial merely 
demonstrates that there has been a significant reduction 
in the patients’ seizures-not abolition of them-once 
on the market, a great deal of experience is needed with 
the drug before its place in the therapeutic armentarium 
is established. 
Lamotrigine is a broad-spectrum antiepileptic drug, 
which is now licensed for monotherapy and may be 
used in newly diagnosed epilepsy. (It was discussed 
earlier in the section on initial treatment.) It has also 
been shown to be effective in Lennox-Gastaut Syn- 
drome, a difficult-to-treat epileptic syndrome of child- 
hood, which is relatively common in the population 
with learning disability’“. Of the other drugs, it is sug- 
gested that vigabatrin is restricted to specialist use (par- 
ticularly until its role in causing peripheral visual loss 
has been fully determined). Some would also consider 
that topiramate is also restricted to specialist use be- 
cause of its side-effect profile: Tiagabine is too new to 
recommend anything but specialist use, and its poten- 
tial to cause visual field loss requires further evaluation. 
Gabapentin is also as effective as standard drugs in new 
onset seizures but its role as a monotherapy drug is as 
yet less clearly defined. 
Experimental drugs 
Patients attending specialist epilepsy clinics may have 
access to potential antiepileptic drugs undergoing 
phase 2 and 3 trials, or may have access to these agents 
on a named patient compassionate use basis in some 
circumstances, with appropriate ethical committee ap- 
proval and informed consent. 
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Other treatment options 
Surgery should be considered fairly early in young peo- 
ple with uncomplicated partial epilepsy originating in 
the temporal lobes and not responding to first-line treat- 
ment with drugs. The results of surgery are good in 
patients who have been appropriately investigated and 
identified as suitable candidates. 
Pre-surgical evaluation requires an experienced 
team. The team will include specialists in neuroradiol- 
ogy, neurophysiology, neuropsychiatry and neuropsy- 
chology as well as in epilepsy and neurosurgery. Ac- 
cess to high quality MRI with the facility for volumet- 
ric measurement of the hippocampi and other imaging 
techniques is essential, as is access to detailed neuro- 
physiology including intracranial recordings. On epi- 
demiological grounds, 30 people per million of the pop- 
ulation per year could be evaluated for epilepsy surgery 
and of these approximately one-third (10 per million) 
would go forward for operation. Of those operated upon 
70-85% would have a very satisfactory outcome (com- 
pletely seizure free or only very occasional seizures). 
Thus a health region with a population of four million 
should be evaluating 120 people per year and operating 
on 40 of these. 
Besides resective surgery for partial epilepsy, the 
same team would be involved in alternative approaches 
such as callosotomy and hemispherectomy for specific 
situations and vagal nerve simulation for intractable 
epilepsy unsuitable for resective surgery. 
It is essential to recognize that suitability for surgery 
depends on ictal EEG and specific MRI criteria, not on 
the result of a random EEG. If curative surgery is done 
too late in the patient’s epileptic career, rehabilitation 
will be difficult. 
Special assessment units 
For patients with ‘epilepsy plus’ where problems in 
diagnosis and treatment cannot be resolved with out- 
patient resources or short-term inpatient admission 
to a neurology service, a more prolonged admission 
to a special epilepsy assessment unit can be benefi- 
cial. In such units the diagnosis can be reassessed, 
seizures intensively monitored and the relationship be- 
tween epilepsy and behaviour evaluated and degrees of 
social handicap, learning difficulties and educational 
problems assessed. Specialized treatment of neuropsy- 
chiatric complications can be carried out and recom- 
mendations made for the most suitable treatment and 
follow-up in medical, psychological and social spheres. 
An assessment admission may last between 6 and 12 
weeks. Approximately 5% of all people with epilepsy 
would benefit from such an admission at some time. 
Some refractory epilepsies may respond to behavioural 
psychotherapy. This needs to be carried out by a psy- 
chiatrist, clinical psychologist or nurse therapist with 
appropriate training. A typical course of treatment takes 
up to 12 one-hour sessions spread over several months. 
A few patients require more, and others, fewer sessions. 
Some children and a smaller number of adults with 
refractory epilepsy respond to a ketogenic diet, such 
as the medium chain triglyceride diet. Specialised 
epilepsy services should have the resources to identify 
potential responders and initiate and monitor treatment. 
Other non-pharmacological treatments are currently 
under evaluation and may be part of a specialized 
epilepsy service. These may include elements of com- 
plementary medicine as well as more orthodox ap- 
proaches. 
Neuropsychiatric follow-up 
Psychiatric morbidity in epilepsy is in excess of that of 
the general population, being present in approximately 
50% of the ‘epilepsy plus’ group (or 1800 per million 
of the population in the community) and in up to 30% 
of all identified patients with epilepsy. 
The excess morbidity includes: 
(a) that caused by the neurological condition that also 
causes the epilepsy; 
(b) mood and behavioural problems related directly in 
time to seizures: 
(c) those unrelated in time to seizure occurrence, in- 
cluding non-epileptic seizures, (pseudoseizures), 
other neurotic conditions, the psychoses of epilepsy 
and other personality and behavioural changes such 
as the sexual disorders of epilepsy; 
(d) drug-related problems. 
Aetiological factors, other than brain disease or mal- 
formation associated with the epilepsy, range from drug 
side effects to the psychosocial consequences of acquir- 
ing the diagnosis of epilepsy. 
Recognition and management of these particular 
conditions are not a significant part of the routine train- 
ing of neurologists, psychiatrists or general practition- 
ers. Because of the interaction between the neurolog- 
ical and psychiatric components and the special treat- 
ment issues involved, any specialized epilepsy service 
must include a neuropsychiatric input. 
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A note on non-epileptic seizures (NES) 
Between lO-20% of patients referred to a specialist 
epilepsy service have seizures that are not epileptic. 
These phenomena are referred to as ‘non-epileptic 
seizures’ (NES) or ‘non-epileptic attack disorder’ 
(NEAD). In Britain a significant number of cases of 
‘status epilepticus’ admitted to hospital are actually 
‘pseudo-status epilepticus’ and the patient may suffer 
iatrogenic damage from overzealous treatment. Pa- 
tients with NEAD referred to specialist units typically 
have a history of frequent hospital admissions with 
a background of social problems and so inappropri- 
ately consume considerable health service resources. 
However, the outcome of treatment of non-epileptic 
seizures in specialist units is good, with fewer hospital 
admissions at follow-up and improvement in social 
functioning. 
Components of the teams needed to address 
these issues 
The team involved in initial diagnosis and stabilization 
should include the following: 
consultant neurologist or epileptologist from an- 
other discipline (neuropsychiatry, clinical pharma- 
cology); 
or paediatric neurologist or paediatrician with ex- 
pertise in epilepsy; 
junior medical staff in training; 
an EEG service providing standard waking EEG 
recordings with simple activation procedures and 
simple video EEG monitoring; 
access to high quality MR scanning and an experi- 
enced neuroradiologist; 
serum drug level monitoring; 
biochemistry, haematology and metabolic screen- 
ing services; 
patient counselling and contact with voluntary 
organizations. This may well be assisted by an 
epilepsy nurse specialist. 
The ‘epilepsy plus’ team must contain the above el- 
ements and in addition should include the following: 
l a neurosurgical team familiar with and experienced 
in epilepsy surgery; 
l a consultant neuropsychiatrist or psychiatrist with 
an interest in epilepsy; 
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clinical psychology and clinical neuropsychology 
services; 
intensive EEG facilities including ambulatory mon- 
itoring, telemetry and intracranial recordings with 
video monitoring; 
a neuroradiologist familiar with the detection of 
mesial temporal sclerosis in MR scans and with 
hippocampal volumetric analysis; 
nursing staff especially attached to the service 
and trained in epilepsy (clinical nurse specialist or 
epilepsy nurse practitioner); 
a special service for adolescents with epilepsy 
(aged 12-18) with appropriate nursing input; 
a special service for women with epilepsy (e.g. 
pre-conception counselling, pregnancy liaison, 
menopause advice) with epilepsy nursing input; 
team members (nursing, medical) familiar with the 
needs of people with learning disability; 
access to dedicated social work services and occu- 
pational therapists; Summaries of epidemiological 
data and service needs per 100 000 population are 
given in Appendix 1. 
SPECIAL ISSUES 
Pregnancy and women’s issues21g22 
Pre-conceptual courtselling 
Pre-conceptual advice about the teratogenicity of 
antiepileptic drugs needs to be given at an early age so 
that specialist help is sought when patients are contem- 
plating a pregnancy. At diagnosis, adolescent girls and 
women of childbearing age should be given informa- 
tion about contraception and pregnancy. They should 
be told that if they wish to become pregnant, they need 
to seek pre-pregnancy counselling and referred to a spe- 
cialist with an interest in the subject. High dose of folate 
supplements (5 mg/day) should be started before con- 
traception is discontinued. This advice should be given 
routinely at the time of an annual epilepsy review or 
during a consultation for contraception. Pre-pregnancy 
counselling issues include the continuing need for treat- 
ment during pregnancy, the most suitable medication 
during pregnancy, and the risk of foetal malformations 
and foetal anticonvulsant syndrome. Many women are 
also worried about the genetics of their seizure disorder. 
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Contraception 
Any possible interactions between the antiepileptic 
drug and the combined oral contraceptive pillZ need to 
be discussed. It should be stressed that non-hormonal 
methods of contraception are not affected by epilepsy. 
Fertility 
The fertility rate of women with epilepsy in the UK 
has been found to be 47.1 (95% CI 42.3-52.4) live 
births/l000 women per year, which is significantly 
lower than that of the general population. Women of 
childbearing age who have epilepsy need to be warned 
that their fertility might be affected by epilepsy and 
possibly by antiepileptic drugs. There have been re- 
cent reports of an association of sodium valproate ther- 
apy with endocrine changes and the polycystic ovary 
syndrome26. If a woman has problems conceiving, she 
needs to seek specialist help. 
Pregnancy 
Once a woman with epilepsy is pregnant, there needs 
to be close liaison between the specialist managing the 
seizure disorder and the obstetrician. These are high- 
risk pregnancies with increased incidence of compli- 
cations and adverse outcomes of pregnancy as well as 
possible alterations in seizure frequency. 
Once a child is born, breast-feeding should be en- 
couraged. Safety in the home and problems of looking 
after a child need to be discussed. If pre-pregnancy 
counselling did not occur and further children are 
wanted, the woman needs to be referred to discuss her 
antiepileptic therapy. 
Menopause 
There is very little data relating to epilepsy and the 
menopause, in particular hormone replacement ther- 
apy. As many women who have been on therapy for 
epilepsy are at a high risk of developing osteoporosis 
and fractures, a trial of hormone replacement therapy 
(HRT) should be given. It is suggested that a progesto- 
gen should always be used with oestrogen in HRT in 
women with epilepsy, even when the uterus is no longer 
present25. 
dren, especially where there may be an incomplete his- 
tory when the person lives alone. Seizures may pose 
a special risk for the elderly, and their onset may be a 
turning point when self-confidence and functional in- 
dependence are lost. Unless the onset of seizures is as- 
sociated with the terminal phase of an illness, patients 
should be referred to a specialist for accurate diagnosis 
and advice about treatment. Secondary prevention of 
strokes is a promising area of development and symp- 
toms caused by a primary or secondary cerebral tumour 
can often be eliminated or ameliorated. 
Special issues in children 
At least 25% of children with epilepsy will have some 
form of special educational needs. At least 20% have 
moderate or severe learning difficulties. The difficulties 
of children who have specific learning difficulties, for 
example, specific reading and writing or specific arith- 
metical problems in association with epilepsy, are often 
under estimated. There is ample evidence that seizure 
discharges interfere with cognitive abilities27. There is 
often an assumption on the part of teachers and other 
non-medical personnel that antiepileptic drugs will dull 
intellectual abilities. Controlled studies of the possible 
cognitive effects of antiepileptic drugs have suggested 
that these are not the main factors responsible for school 
difficulties, but that the underlying pathology, of which 
epilepsy is the symptom, is crucial. 
It is important that the difficulties experienced by 
children with epilepsy at school are clearly identified 
and addressed. Liaison between consultant-led paedi- 
atric services, education authorities and school staff is 
often less than idea128, yet, good practice today will 
have beneficial consequences for tomorrow’s adults 
and implications for long-term service provision. Com- 
munity paediatricians should be aware of special ed- 
ucational resources for children with epilepsy. When 
the medical contribution to an educational needs as- 
sessment is being written, this should contain relevant 
information about seizure type, syndrome and aetiol- 
ogy, together with an account of the effect the epilepsy 
and its treatment are having in the classroom. This will 
require liaison between the community paediatrician, 
the epilepsy team and health visitor and community 
nurse services. 
Epilepsy in older people 
Epilepsy in adults with learning disability 
The incidence of epilepsy is bi-modal, and increases in 
older age groups when partial seizures become more 
common. Cerebral atherosclerosis and tumours are the 
main causes. Ten percent of patients suffering a stroke 
have seizures within 5 years. Epilepsy may present dif- 
ferently in older people than in young adults and chil- 
‘Learning disability’ (LD) is the term used in the UK 
to refer to what is elsewhere called ‘mental retarda- 
tion’. Epilepsy is common in this population, the like- 
lihood increasing with severity of LD and presence 
of associated conditions2g-31. About 30% of patients 
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who are in touch with LD services have a diagnosis 
of epilepsy and this may approach 50% in institutional 
populations. Even in those with mild learning disability 
the prevalence rate is about 6%, ten times greater than 
in the general population32T33. Furthermore, there are 
epilepsy syndromes that tend to be associated with LD 
and in which the seizures can be difficult to treat, such 
as Lennox-Gastaut syndrome. Disability awareness is 
currently not a part of routine neurology training. LD 
teams that are properly resourced play a crucial part in 
the management of epilepsy in this group of patients, 
and medical staff specializing in LD may acquire the 
necessary skills. Epilepsy tends to be more refractory 
in this group, and patients need ongoing contact with 
specialist services. People with LD and those without 
should have equity of access to quality services3’. Rec- 
ognizing this still requires a culture shift among some 
staff working in radiology and neurophysiology de- 
partments, local standards could be set to ensure that 
an expected level of service is achieved. 
Status epilepticus 
Status epilepticus is defined as a condition in which 
epileptic activity persists for 30 minutes or more. This 
can result in a wide spectrum of clinical symptoms and 
have a highly variable pathophysiological, anatomical 
and aetiological basis. One calculation of the frequency 
of status epilepticus in the general population suggests 
that there are over 50 cases/l00000 persons per year 
(approximately 30 000 cases in the UK each year), but 
other estimates are much higher. The condition is com- 
mon in children. Over 50% of cases occur due to an 
acute cerebral event in patients without a prior history 
of epilepsy. In patients with established epilepsy, the 
frequency of status is highest in those with chronic 
or severe epilepsy, additional handicaps, learning dis- 
ability or structural cerebral damage (particularly in 
the frontal lobe). The differentiation of pseudo-status 
epilepticus (a psychologically determined condition) 
can pose problems and due attention should be taken 
to the previous medical history. Most forms of sta- 
tus epilepticus are emergencies, requiring admission 
to hospital and emergency therapy. Tonic-clonic status 
epilepticus (convulsive status epilepticus) is the most 
typical form, and canies a mortality rate of about 20% 
and a higher rate of neurological morbidity. Much of 
the morbidity and mortality is due to the underlying 
cause of the status, but is exacerbated by inappropriate 
or inadequate treatment’“. All casualty and neurologi- 
cal departments should have a treatment protocol, such 
as that shown in Appendix 2. The treatment of con- 
vulsive status is staged into therapy for early status, 
established and refractory status. Refractory convul- 
sive status epilepticus requires admission to an Inten- 
sive Care Unit, with access to EEG monitoring. Non- 
convulsive forms of status do not usually require emer- 
gency therapy367 37. 
Long-term care 
Approximately 700 people per million of the popu- 
lation may require long-term care because of epilepsy 
and associated problems. This is most commonly due to 
refractory epilepsy in association with learning disabil- 
ity, though associated psychiatric illness or any combi- 
nation of these factors may be relevant. Responsibility 
for placement frequently lies with local authority social 
services, but the additional health-related costs should 
be borne by health authorities of origin, and budgetary 
allowance should therefore be made for this. It is un- 
acceptable that access to services should be denied or 
delayed because of the failure of social services de- 
partments and health authorities to come to joint ar- 
rangements about funding. This has happened all too 
often in the past. The current government policy to en- 
courage joint commissioning of services may help to 
make the service more seamless to the user. Where such 
arrangements are in place it is important that commis- 
sioning agencies specify the health component prop- 
erly fo! people with epilepsy. 
RESOURCE IMPLICATIONS 
The consistent delivery of high-quality cost-effective 
services to people will mean improving the training of 
doctors and nurses and other health professionals and 
the education of managers and purchasers. Neurophys- 
iology and scanning facilities will need to be expanded 
and made ‘user friendly’ for the large number of leam- 
ing disabled patients that will need to use them. 
Undergraduate medical education in epilepsy will 
need to be enhanced (as will nurse education) and clin- 
icians encouraged to use epilepsy in special study mod- 
ules in the new undergraduate curriculum (as already 
happens in the University of Birmingham). Senior and 
junior trainees in hospital practice (particularly in neu- 
rophysiology, neurology, psychiatry and learning dis- 
ability) will need to spend time in quality epilepsy units 
and clinics. Doctors training in primary care should be 
exposed to epilepsy experience (auditing their practices 
in epilepsy care is a useful exercise). 
Community paediatricians need better training in the 
complex needs of the child with epilepsy (particularly 
those with learning difficulties or physical handicap). 
Practice nurse training (particularly to set up mini- 
clinics in primary care) is essential and models already 
exist as to how this should be done38. There has been an 
expansion of specialist nurses in epilepsy who need ap- 
propriate high level training: the development of high 
quality distance learning university courses such as that 
offered by Leeds Metropolitan University is to be com- 
mended. 
The voluntary organizations for people with epilepsy 
have an important role in general education, in reduc- 
ing stigma and in educating people with epilepsy to 
demand better services-‘patient power’ can become 
a reality. 
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